Treatment of inflammatory lung diseases with combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate

Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An in vitro study.

Article specifications

This study was published in 2018 in Journal of Eur J Pharm Sci. (IF 2009:1.88) by Italian and Australian specialists. The aim was to understand if the combination HA-CL - SAP had an enhanced activity with respect to the combination native hyaluronic acid (HA) - SAP and the single SAP, HA and HA-CL components.

 

Results

These preliminary results showed that the combination HA-CL - SAP could be suitable to reduce inflammation and oxidative stress in lung disorders like acute respiratory distress syndrome, asthma, emphysema and chronic obstructive pulmonary disease, where inflammation is prominent.